Impact of Anti-TNFα Treatment on the Humoral Response to the BNT162b2 mRNA COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease Patients
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Study Procedures
2.3. Statistical Analysis
3. Results
3.1. Patients’ Characteristics
3.2. Anti-SARS-CoV-2 S Antibody Concentrations after the Initial Vaccine Series
3.3. Anti-SARS-CoV-2 S Antibody Concentrations at Different Time Points after the Initial Vaccine Series
3.4. Anti-SARS-CoV-2 S Antibody Levels after the Third Vaccination
3.5. Short-term AEs after the First and Second Vaccinations
3.6. Breakthrough Infection
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [Google Scholar] [CrossRef]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Marc, G.P.; Moreira, E.D.; Zerbini, C. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
- Liu, W.; Zhang, Q.; Chen, J.; Xiang, R.; Song, H.; Shu, S.; Chen, L.; Liang, L.; Zhou, J.; You, L. Detection of COVID-19 in children in early January 2020 in Wuhan, China. N. Engl. J. Med. 2020, 382, 1370–1371. [Google Scholar] [CrossRef]
- Qiu, H.; Wu, J.; Hong, L.; Luo, Y.; Song, Q.; Chen, D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: An observational cohort study. Lancet Infect Dis. 2020, 20, 689–696. [Google Scholar] [CrossRef]
- Dong, Y.; Mo, X.; Hu, Y.; Qi, X.; Jiang, F.; Jiang, Z.; Tong, S. Epidemiology of COVID-19 among children in China. Pediatrics 2020, 145, e20200702. [Google Scholar] [CrossRef]
- Kainth, M.K.; Goenka, P.K.; Williamson, K.A.; Fishbein, J.S.; Subramony, A.; Barone, S.; Belfer, J.A.; Feld, L.M.; Krief, W.I.; Palumbo, N.; et al. Early Experience of COVID-19 in a US Children’s Hospital. Pediatrics 2020, 146, e2020003186. [Google Scholar] [CrossRef]
- Frenck, R.W., Jr.; Klein, N.P.; Kitchin, N.; Gurtman, A.; Absalon, J.; Lockhart, S.; Perez, J.L.; Walter, E.B.; Senders, S.; Bailey, R. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N. Engl. J. Med. 2021, 385, 239–250. [Google Scholar] [CrossRef]
- Napuri, N.I.; Curcio, D.; Swerdlow, D.L.; Srivastava, A. Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review. Infect. Dis. Ther. 2022, 11, 1391–1414. [Google Scholar] [CrossRef]
- Wellens, J.; Colombel, J.-F.; Satsangi, J.J.; Wong, S.-Y. SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges. J. Crohn’s Colitis 2021, 15, 1376–1386. [Google Scholar] [CrossRef]
- Edelman-Klapper, H.; Zittan, E.; Bar-Gil Shitrit, A.; Rabinowitz, K.M.; Goren, I.; Avni-Biron, I.; Ollech, J.E.; Lichtenstein, L.; Banai-Eran, H.; Yanai, H.; et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology 2022, 162, 454–467. [Google Scholar] [CrossRef]
- Kennedy, N.A.; Lin, S.; Goodhand, J.R.; Chanchlani, N.; Hamilton, B.; Bewshea, C.; Nice, R.; Chee, D.; Cummings, J.F.; Fraser, A.; et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 2021, 70, 1884–1893. [Google Scholar] [CrossRef]
- Doherty, J.; Morain, N.O.; Stack, R.; Girod, P.; Tosetto, M.; Inzitiari, R.; Sheridan, J.; Cullen, G.; Mc Dermott, E.; Buckley, M.; et al. Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-CoV-2 ImmunisatiON). J. Crohn’s Colitis 2022, 16, 1354–1362. [Google Scholar] [CrossRef]
- Kennedy, N.A.; Goodhand, J.R.; Bewshea, C.; Nice, R.; Chee, D.; Lin, S.; Chanchlani, N.; Butterworth, J.; Cooney, R.; Croft, N.M. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut 2021, 70, 865–875. [Google Scholar] [CrossRef]
- Shire, Z.J.; Reicherz, F.; Lawrence, S.; Sudan, H.; Golding, L.; Majdoubi, A.; Levett, P.N.; Lavoie, P.M.; Jacobson, K. Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy. Gut 2021, 71, 1922–1924. [Google Scholar] [CrossRef]
- Dailey, J.; Kozhaya, L.; Dogan, M.; Hopkins, D.; Lapin, B.; Herbst, K.; Brimacombe, M.; Grandonico, K.; Karabacak, F.; Schreiber, J.; et al. Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease. Inflamm. Bowel. Dis. 2021, 28, 1019–1026. [Google Scholar] [CrossRef]
- Cotugno, N.; Franzese, E.; Angelino, G.; Amodio, D.; Romeo, E.F.; Rea, F.; Faraci, S.; Tambucci, R.; Profeti, E.; Manno, E.C. Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens. Vaccines 2022, 10, 1109. [Google Scholar] [CrossRef]
- Muench, P.; Jochum, S.; Wenderoth, V.; Ofenloch-Haehnle, B.; Hombach, M.; Strobl, M.; Sadlowski, H.; Sachse, C.; Torriani, G.; Eckerle, I. Development and validation of the elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J. Clin. Microbiol. 2020, 58, e01694-20. [Google Scholar] [CrossRef]
- Alexander, J.L.; Kennedy, N.A.; Ibraheim, H.; Anandabaskaran, S.; Saifuddin, A.; Castro Seoane, R.; Liu, Z.; Nice, R.; Bewshea, C.; D'Mello, A.; et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): A multicentre, prospective, case-control study. Lancet. Gastroenterol. Hepatol. 2022, 7, 342–352. [Google Scholar] [CrossRef]
- Jena, A.; James, D.; Singh, A.K.; Dutta, U.; Sebastian, S.; Sharma, V. Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis. Clin. Gastroenterol. Hepatol. 2022, 20, 1456–1479.e18. [Google Scholar] [CrossRef]
- Lev-Tzion, R.; Focht, G.; Lujan, R.; Mendelovici, A.; Friss, C.; Greenfeld, S.; Kariv, R.; Ben-Tov, A.; Matz, E.; Nevo, D.; et al. COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated with Disease Exacerbation. Clin. Gastroenterol. Hepatol. 2022, 20, e1263–e1282. [Google Scholar] [CrossRef]
- Andrews, N.; Stowe, J.; Kirsebom, F.; Toffa, S.; Rickeard, T.; Gallagher, E.; Gower, C.; Kall, M.; Groves, N.; O’Connell, A.-M. COVID-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant. N. Engl. J. Med. 2022, 386, 1532–1546. [Google Scholar] [CrossRef] [PubMed]
- Melmed, G.Y.; Botwin, G.J.; Sobhani, K.; Li, D.; Prostko, J.; Figueiredo, J.; Cheng, S.; Braun, J.; McGovern, D.P. Antibody responses after SARS-CoV-2 mRNA vaccination in adults with inflammatory bowel disease. Ann. Intern. Med. 2021, 174, 1768–1770. [Google Scholar] [CrossRef] [PubMed]
- Charilaou, P.; Tricarico, C.; Battat, R.; Scherl, E.J.; Longman, R.S.; Lukin, D.J. Impact of inflammatory bowel disease therapies on durability of humoral response to SARS-CoV-2 vaccination. Clin. Gastroenterol. Hepatol. 2022, 20, e1493–e1499. [Google Scholar] [CrossRef] [PubMed]
- Lin, S.; Kennedy, N.A.; Saifuddin, A.; Sandoval, D.M.; Reynolds, C.J.; Seoane, R.C.; Kottoor, S.H.; Pieper, F.P.; Lin, K.-M.; Butler, D.K.; et al. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat. Commun. 2022, 13, 1379. [Google Scholar] [CrossRef]
- Reuken, P.A.; Andreas, N.; Grunert, P.C.; Glockner, S.; Kamradt, T.; Stallmach, A. T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease. J. Crohn’s Colitis 2022, 16, 251–258. [Google Scholar] [CrossRef]
- Li, D.; Xu, A.; Mengesha, E.; Elyanow, R.; Gittelman, R.M.; Chapman, H.; Prostko, J.C.; Frias, E.C.; Stewart, J.L.; Pozdnyakova, V. The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders. Inflamm. Bowel. Dis. 2021, 28, 1130–1133. [Google Scholar] [CrossRef]
- Krasselt, M.; Wagner, U.; Nguyen, P.; Pietsch, C.; Boldt, A.; Baerwald, C.; Pierer, M.; Seifert, O. Humoral and Cellular Response to COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases under Real-life Conditions. Rheumatology 2022, 61, SI180–SI188. [Google Scholar] [CrossRef]
- Alexander, J.L.; Selinger, C.P.; Powell, N. Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease. Lancet. Gastroenterol. Hepatol. 2021, 6, 987–988. [Google Scholar] [CrossRef]
- Singh, P.; Tuck, C.; Gibson, P.R.; Chey, W.D. Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines among Patients with Inflammatory Bowel Diseases. Am. J. Gastroenterol. 2022, 117, 462–469. [Google Scholar]
- Schell, T.L.; Knutson, K.L.; Saha, S.; Wald, A.; Phan, H.S.; Almasry, M.; Chun, K.; Grimes, I.; Lutz, M.; Hayney, M.S. Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients with Inflammatory Bowel Disease. Inflamm. Bowel. Dis. 2022, izac082. [Google Scholar] [CrossRef]
- Nemet, I.; Kliker, L.; Lustig, Y.; Zuckerman, N.; Erster, O.; Cohen, C.; Kreiss, Y.; Alroy-Preis, S.; Regev-Yochay, G.; Mendelson, E. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N. Engl. J. Med. 2022, 386, 492–494. [Google Scholar] [CrossRef] [PubMed]
- Caron, B.; Neuville, E.; Peyrin-Biroulet, L. Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients’ Survey. Dig. Dis. Sci. 2022, 67, 2067–2073. [Google Scholar] [CrossRef] [PubMed]
- Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2021, 27, 225–228. [Google Scholar] [CrossRef] [PubMed]
- Garrido, I.; Lopes, S.; Macedo, G. Safety of COVID-19 Vaccination in Inflammatory Bowel Disease Patients on Biologic Therapy. J. Crohn’s Colitis 2022, 16, 687–688. [Google Scholar] [CrossRef]
- Botwin, G.J.; Li, D.; Figueiredo, J.; Cheng, S.; Braun, J.; McGovern, D.P.; Melmed, G.Y. Adverse events following SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am. J. Gastroenterol. 2021, 116, 1746–1751. [Google Scholar]
- Weaver, K.N.; Zhang, X.; Dai, X.; Watkins, R.; Adler, J.; Dubinsky, M.C.; Kastl, A.; Bousvaros, A.; Strople, J.A.; Cross, R.K. Impact of SARS-CoV-2 vaccination on inflammatory bowel disease activity and development of vaccine-related adverse events: Results from PREVENT-COVID. Inflamm. Bowel. Dis. 2021, izab302. [Google Scholar] [CrossRef]
- Rabinowitz, K.M.; Navon, M.; Edelman-Klapper, H.; Zittan, E.; Bar-Gil Shitrit, A.; Goren, I.; Avni-Biron, I.; Ollech, J.E.; Lichtenstein, L.; Banai-Eran, H.; et al. Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases. Vaccines 2022, 10, 1186. [Google Scholar] [CrossRef]
- Wan, Y.; Shang, J.; Sun, S.; Tai, W.; Chen, J.; Geng, Q.; He, L.; Chen, Y.; Wu, J.; Shi, Z.; et al. Molecular Mechanism for Antibody, Dependent Enhancement of Coronavirus Entry. J. Virol. 2020, 94, e02015–e02019. [Google Scholar] [CrossRef]
- Liu, Y.; Soh, W.T.; Kishikawa, J.-I.; Hirose, M.; Nakayama, E.E.; Li, S.; Sasai, M.; Suzuki, T.; Tada, A.; Arakawa, A.; et al. An infectivity- enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell 2021, 184, 3452–3466. [Google Scholar] [CrossRef]
Variable | Overall (n = 63) | Patients on Anti-TNFα (n = 11) | Patients on Non-Anti-TNFα (n = 31) | Patients on 5-ASA (n = 21) | |
---|---|---|---|---|---|
Age (years) | 15.2 (9.6–17.9) | 13.3 (9.6–17.9) | 16.1 (12.3–17.9) | 14.6 (11.8–17.9) | |
Sex | Female | 46.0% (29/63) | 45.5% (5/11) | 53.3% (16/31) | 36.4% (8/21) |
Male | 54.0% (34/63) | 54.5% (6/11) | 48.4% (15/31) | 61.9% (13/21) | |
Diagnosis | CD | 31.7% (20/63) | 63.6% (7/11) | 33.3% (10/31) | 13.6% (3/21) |
UC | 68.3% (43/63) | 36.4% (4/11) | 67.7% (21/31) | 85.7% (18/21) | |
Medications (Other than anti-TNFα and 5-ASA) | UST | 17.5% (11/63) | 0 | 36.7% (11/31) | 0 |
IM (AZA/6-MP) | 49.2% (31/63) | 54.5% (6/11) | 83.9% (26/31) | 0 | |
Time from the beginning of the IBD treatment to the second vaccination (months) | 21 (8–46) | 18 (13–44) | 34 (14–53) | 10 (2–24) | |
Serum samples for analysis of antibody titers after the initial two vaccine doses | Total | 145 | 18.6% (27/145) | 49.7% (72/145) | 31.7% (46/145) |
3–9 weeks | 50 | 20.0% (10/50) | 44.0% (22/50) | 36.0% (18/50) | |
10–16 weeks | 50 | 18.0% (9/50) | 52.% (26/50) | 30.0% (15/50) | |
20–28 weeks | 45 | 17.8% (8/45) | 53.3% (24/45) | 28.9% (13/45) | |
Time from the initial two vaccine doses to the analysis of serum (days) | 3–9 weeks | 39 (21–63) | 45 (21–63) | 41 (21–63) | 38 (21–63) |
10–16 weeks | 93 (72–112) | 94 (79–109) | 93 (72–112) | 94 (77–113) | |
20–28 weeks | 170 (140–196) | 179 (168–194) | 169 (141–196) | 167 (140–194) | |
Patients with the third vaccination | 36.5% (23/63) | 54.5% (6/11) | 41.9% (13/31) | 19.0% (4/21) | |
Serum samples for analysis of antibody titers after the third vaccination | 11 | 45.5% (5/11) | 36.4% (4/11) | 9.0% (1/11) | |
Time from the third vaccination to the analysis of serum (days) | 222 (184–284) | 236 (216–276) | 219 (186–276) | 208 (187–284) | |
COVID-19 (Breakthrough infection) | 12.7% (8/63) | 9.1% (1/11) | 9.7% (3/31) | 18.2% (4/21) | |
Duration until COVID-19 infection after the second vaccination (days) | 146 (117–176) | 176 | 135 (121–154) | 135.5 (117–173) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kashiwagi, K.; Jimbo, K.; Suzuki, M.; Arai, N.; Kudo, T.; Shimizu, T. Impact of Anti-TNFα Treatment on the Humoral Response to the BNT162b2 mRNA COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease Patients. Vaccines 2022, 10, 1618. https://doi.org/10.3390/vaccines10101618
Kashiwagi K, Jimbo K, Suzuki M, Arai N, Kudo T, Shimizu T. Impact of Anti-TNFα Treatment on the Humoral Response to the BNT162b2 mRNA COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease Patients. Vaccines. 2022; 10(10):1618. https://doi.org/10.3390/vaccines10101618
Chicago/Turabian StyleKashiwagi, Kosuke, Keisuke Jimbo, Mitsuyoshi Suzuki, Nobuyasu Arai, Takahiro Kudo, and Toshiaki Shimizu. 2022. "Impact of Anti-TNFα Treatment on the Humoral Response to the BNT162b2 mRNA COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease Patients" Vaccines 10, no. 10: 1618. https://doi.org/10.3390/vaccines10101618
APA StyleKashiwagi, K., Jimbo, K., Suzuki, M., Arai, N., Kudo, T., & Shimizu, T. (2022). Impact of Anti-TNFα Treatment on the Humoral Response to the BNT162b2 mRNA COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease Patients. Vaccines, 10(10), 1618. https://doi.org/10.3390/vaccines10101618